1. Home
  2. INDP vs ONT Comparison

INDP vs ONT Comparison

Compare INDP & ONT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

N/A

Current Price

$3.08

Market Cap

438.4M

Sector

Health Care

ML Signal

N/A

Logo Onterris Inc. Common Stock

ONT

Onterris Inc. Common Stock

N/A

Current Price

$14.87

Market Cap

503.6M

ML Signal

N/A

Company Overview

Basic Information
Metric
INDP
ONT
Founded
2000
2012
Country
United States
United States
Employees
N/A
3500
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
438.4M
503.6M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
INDP
ONT
Price
$3.08
$14.87
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $18.20
AVG Volume (30 Days)
373.1K
★ 619.2K
Earning Date
11-11-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 93.69
EPS
★ N/A
N/A
Revenue
N/A
★ $830,538,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8.17
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 19.26
52 Week Low
$0.92
$12.35
52 Week High
$5.96
$23.32

Technical Indicators

Market Signals
Indicator
INDP
ONT
Relative Strength Index (RSI) 53.64 52.09
Support Level $2.05 $14.39
Resistance Level $3.84 $18.32
Average True Range (ATR) 0.32 0.76
MACD 0.04 0.23
Stochastic Oscillator 69.24 85.68

Price Performance

Historical Comparison
INDP
ONT

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About ONT Onterris Inc. Common Stock

Onterris Inc is an environmental solutions company. The company provides environmental solutions to organizations addressing regulatory, operational, and environmental challenges. Its services include the application of scientific, engineering, and data-driven approaches to support risk management, compliance, and environmental protection, including air, water, and soil.

Share on Social Networks: